vorinostat
Selected indexed studies
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. (Lancet Oncol, 2018) [PMID:30100375]
- Vorinostat as potential antiparasitic drug. (Eur Rev Med Pharmacol Sci, 2020) [PMID:32706080]
- Repurposing Vorinostat for the Treatment of Disorders Affecting Brain. (Neuromolecular Med, 2021) [PMID:33948878]
_Worker-drafted node — pending editorial review._
Connections
vorinostat is a side effect of
Sources
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. (2018) pubmed
- Vorinostat as potential antiparasitic drug. (2020) pubmed
- Repurposing Vorinostat for the Treatment of Disorders Affecting Brain. (2021) pubmed
- Vorinostat in autophagic cell death: A critical insight into autophagy-mediated, -associated and -dependent cell death for cancer prevention. (2022) pubmed
- Vorinostat. (2007) pubmed
- Vorinostat for treatment-refractory bullous pemphigoid. (2023) pubmed
- Vorinostat in solid and hematologic malignancies. (2009) pubmed
- Vorinostat restores iNKT cell functionality in aggressive cholangiocarcinoma. (2025) pubmed
- Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. (2010) pubmed
- The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs. (2023) pubmed